India Generics Makers Dominate U.S. Market Despite U.S. FDA Crackdowns
This article was originally published in PharmAsia News
Despite an increasing oversight of India's drug production by U.S. FDA, domestic pharmas have achieved clearances for more than 100 generic drugs in the U.S. this year, accounting for nearly 40% of all approvals.
You may also be interested in...
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.